Altria Group, Inc. — 5.6/10
Altria Group is a US tobacco company built around the dominant Marlboro cigarette franchise, with smaller positions in oral tobacco (Copenhagen, Skoal, on!) and e-vapor (NJOY). The smokeable segment is ~88% of revenue and is a textbook 3-player US cigarette oligopoly in which Marlboro holds ~40.5% of the total category and PM USA is the clear price-setter. Revenue erodes ~2–3%/yr as cigarette volumes fall ~10%/yr faster than pricing offsets, but relentless margin engineering and a steady buyback compound adjusted EPS at a stable +4–6%.
The core tension: MO is the king of a declining theme and a minor player in the growing ones. It clears all three hard quality gates — oligopoly YES, positive/growing FCF YES, management track record YES — so no cap applies. But the two highest-weighted dimensions (Financial Trends, Thematic Exposure) both land at 5 because the dominant franchise is in secular volume decline while the growing nicotine themes (oral pouches ~24% CAGR, e-vapor) are precisely where MO is sub-scale and losing share (on! ~15.6% and falling vs ZYN; NJOY ~2.5%, impaired $1.3B in Q4'25). High quality, no growth.
| CEO | Billy Gifford (since 2020) | Revenue Trend | Declining (-2.7% 5yr CAGR) |
| Core Franchise | Marlboro ~40.5% US cigarettes | Free Cash Flow | ~$9B (~37% margin) |
| Dividend | 5.75% yield, 60-yr increase streak | FYE | December 31 |
| Quality Gate | PASS (0 NOs) | Smokeable Margin Trend | Expanding (+580bps 5yr) |
| Dimension | Score | Weight | Weighted |
|---|---|---|---|
| Financial Trends | 5 | 25% | 1.25 |
| Thematic Exposure | 5 | 35% | 1.75 |
| Management Quality | 7 | 20% | 1.40 |
| Investor Sentiment (Inverted) | 6 | 5% | 0.30 |
| Concerns / Risks | 6 | 15% | 0.90 |
| Composite | 100% | 5.6 |
A genuinely high-quality, gate-clearing business — dominant oligopolist, ~$9B FCF, flawless management track record, best-in-class capital return — that is nonetheless structurally no-growth. The composite sits at 5.6/10 rather than 7+ because the two heaviest-weighted dimensions (Financial Trends and Thematic Exposure) both anchor at 5: the dominant ~88%-of-revenue smokeable franchise is in secular ~10%/yr volume decline, and the growing nicotine themes are exactly where MO is sub-scale and losing share.
Quality gate: PASS (0 NOs). Oligopoly YES (Marlboro ~40.5% of the US cigarette market, a ≤3-player oligopoly). Positive & growing FCF YES (~$9B at a ~37% margin, +5.4% in FY2025). Management track record YES (stable C-suite, ~100% hit rate on trackable commitments). No cap applies; the raw weighted composite stands as the final score.
Altria's financial profile is the textbook tobacco model: a slowly shrinking revenue base (-2.7% 5yr CAGR, cigarette volumes down high-single-digits offset by ~+8% net pricing) paired with relentless profitability engineering. The smokeable segment's adjusted OCI margin has climbed ~580bps to 63.4% and FCF holds near $9B, funding a ~2%/yr buyback that compounds adjusted EPS at a steady +4–6% even as the top line falls. There is no growing theme large enough to re-rate the name.
The 7/10 management read and the constructive inverted-sentiment and risk reads lift the composite off a pure "5." Management is a model of consistency and shareholder-return discipline, and there is a real management-Street divergence (the duty-drawback thesis) the Street won't underwrite. Below-peer valuation (~12.9x vs ~15.3x), zero China exposure, and a de-risked regulatory backdrop after the federal menthol-ban withdrawal round out a defensible defensive setup.
Own it for the dividend and defensiveness, not for growth or a re-rate. The below-peer multiple may be deserved rather than a discount — the below-peer growth profile and the absence of a large growing theme are the binding constraints.